Pharmaceutical Technology chats with Roger Viney from ICE Pharma about bile acids in detail, including how they are useful in helping to improve drug solubility and absorption.
Poor solubility and bioavailability are becoming increasingly problematic for drug developers as more complex molecules are entering the development pipeline. “Bile acids are nature’s surfactants, their primary role is to promote the absorption of fat-soluble nutrients,” says Roger Viney, PhD, chief commercial officer for ICE Pharma—a bile acid expert. “So, depending on the bile acid, you can vary the hydrophilic lipophilic balance [and] improve bioavailability of poorly soluble drugs.”
“Furthermore, the bile acids can play a role as enhancer of permeability,” Viney continues. “[Bile acids are] able to modulate the cell membranes to allow certain drugs to cross the biological barriers more effectively. So, we have examples today, existing examples of oral and injectable applications formulations that use bile acids as excipients, and we are expecting to see this expand into things like transdermal and even nasal applications.”
Bile acids have been used in traditional forms of medicine for thousands of years; however, they did not enter modern and Western medicines until the 1960s, Viney notes. “The past 20 years have seen a very significant amount of research done into bile acids and their recognition that they're more than nature's surfactants, that they're, in fact, signaling molecules that have metabolic function,” he adds. “And so, this kind of research has opened up a whole new field where bile acids can potentially treat oncology, liver diseases, even neurodegenerative diseases.”
Click above to watch the full interview
Roger Viney, PhD, is the chief commercial officer for ICE Pharma and is responsible for the global commercial functions. Roger has a 30-year career, starting in R&D and then moving across to sales, marketing, key account management, and business and product management for the pharma market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.